Onconova Therapeutics Q3 EPS $(0.23) Beats $(0.29) Estimate, Sales $57.00K Miss $70.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Onconova Therapeutics (NASDAQ:ONTX) reported Q3 earnings with an EPS loss of $(0.23), which was better than the expected $(0.29) estimate, marking a 20.69% beat and an 11.54% improvement from the previous year. However, sales of $57.00K fell short of the $70.00K estimate by 18.57%, remaining flat compared to the same period last year.
November 14, 2023 | 9:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Onconova Therapeutics reported a smaller-than-expected EPS loss in Q3 but missed sales estimates, with no sales growth compared to last year.
The better-than-expected EPS might be viewed positively by investors, indicating some level of operational efficiency or cost control. However, the miss on sales and lack of growth could raise concerns about the company's revenue-generating ability. The mixed results lead to a neutral short-term impact score, as the positive EPS surprise could be offset by the negative sales performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100